174 related articles for article (PubMed ID: 3928007)
1. Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Close SP; Marriott AS; Pay S
Br J Pharmacol; 1985 Jun; 85(2):320-2. PubMed ID: 3928007
[TBL] [Abstract][Full Text] [Related]
2. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Nomoto M; Jenner P; Marsden CD
Neurosci Lett; 1985 Jun; 57(1):37-41. PubMed ID: 3162113
[TBL] [Abstract][Full Text] [Related]
3. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Gnanalingham KK; Erol DD; Hunter AJ; Smith LA; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(3):275-86. PubMed ID: 7770603
[TBL] [Abstract][Full Text] [Related]
4. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
[TBL] [Abstract][Full Text] [Related]
5. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(3):287-97. PubMed ID: 7770604
[TBL] [Abstract][Full Text] [Related]
6. The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset.
Nomoto M; Jenner P; Marsden CD
Neurosci Lett; 1988 Nov; 93(2-3):275-80. PubMed ID: 2907373
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
Elliott PJ; Walsh DM; Close SP
Neurosci Lett; 1992 Aug; 142(1):1-4. PubMed ID: 1357609
[TBL] [Abstract][Full Text] [Related]
8. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD
Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758
[TBL] [Abstract][Full Text] [Related]
9. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T
Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249
[TBL] [Abstract][Full Text] [Related]
10. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Boyce S; Rupniak NM; Steventon MJ; Iversen SD
Neurology; 1990 Jun; 40(6):927-33. PubMed ID: 2140595
[TBL] [Abstract][Full Text] [Related]
12. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Domino EF; Sheng J
J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
[TBL] [Abstract][Full Text] [Related]
13. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Waters CM; Hunt SP; Jenner P; Marsden CD
Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993
[TBL] [Abstract][Full Text] [Related]
14. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.
Temlett JA; Chong PN; Oertel WH; Jenner P; Marsden CD
Eur J Pharmacol; 1988 Nov; 156(2):197-206. PubMed ID: 2977118
[TBL] [Abstract][Full Text] [Related]
15. Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease.
Andringa G; Vermeulen RJ; Drukarch B; Stoof JC; Cools AR
Adv Pharmacol; 1998; 42():792-5. PubMed ID: 9328017
[No Abstract] [Full Text] [Related]
16. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
17. A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys.
Wolters EC; Kebabian JC; Guttman M; Mak E; Pate BD; Calne DB
Neurosci Lett; 1988 Dec; 95(1-3):257-61. PubMed ID: 3265771
[TBL] [Abstract][Full Text] [Related]
18. Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease.
Close SP; Elliott PJ; Hayes AG; Marriott AS
Psychopharmacology (Berl); 1990; 102(3):295-300. PubMed ID: 1979176
[TBL] [Abstract][Full Text] [Related]
19. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Yoshimura N; Mizuta E; Kuno S; Sasa M; Yoshida O
Neuropharmacology; 1993 Apr; 32(4):315-21. PubMed ID: 8098860
[TBL] [Abstract][Full Text] [Related]
20. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
Allen JM; Cross AJ; Yeats JC; Ghatei MA; McGregor GP; Close SP; Pay S; Marriott AS; Tyers MB; Crow TJ
Brain; 1986 Feb; 109 ( Pt 1)():143-57. PubMed ID: 2417654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
